MAXIMIZING ONCOLOGY RESEARCH WITH INTEGRATED KRAS ASSAY COMPANIES AND RAS ASSAYS

during the quickly evolving discipline of oncology analysis, correct and productive mutation screening is crucial for producing specific therapies. The KRAS companies Platform plays a pivotal position On this landscape by offering extensive options for KRAS mutation profiling and Examination. KRAS mutations, found in about ninety five% of RAS-relat